These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23570194)

  • 41. Neuropsychiatric update: neuroimaging schizophrenia.
    Kile SJ
    Psychopharmacol Bull; 2007; 40(4):156-67. PubMed ID: 18227785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroimaging of serotonin system in anxiety disorders.
    Maron E; Nutt D; Shlik J
    Curr Pharm Des; 2012; 18(35):5699-708. PubMed ID: 22632475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The nucleus accumbens as part of a basal ganglia action selection circuit.
    Nicola SM
    Psychopharmacology (Berl); 2007 Apr; 191(3):521-50. PubMed ID: 16983543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imaging the Nonmotor Symptoms in Parkinson's Disease.
    Yousaf T; Wilson H; Politis M
    Int Rev Neurobiol; 2017; 133():179-257. PubMed ID: 28802921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An intact dopaminergic system is required for context-conditioned release of 5-HT in the nucleus accumbens of postweaning isolation-reared rats.
    Fulford AJ; Marsden CA
    Neuroscience; 2007 Oct; 149(2):392-400. PubMed ID: 17869434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.
    Erritzoe D; Talbot P; Frankle WG; Abi-Dargham A
    Neuroimaging Clin N Am; 2003 Nov; 13(4):817-32. PubMed ID: 15024964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature.
    Narendran R; Martinez D
    Synapse; 2008 Nov; 62(11):851-69. PubMed ID: 18720516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and "intrasynaptic" transmitter.
    Innis RB
    Adv Pharmacol; 1998; 42():215-9. PubMed ID: 9327882
    [No Abstract]   [Full Text] [Related]  

  • 52. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
    Masana M; Bortolozzi A; Artigas F
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):53-68. PubMed ID: 20701825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.
    Kegeles LS; Abi-Dargham A; Frankle WG; Gil R; Cooper TB; Slifstein M; Hwang DR; Huang Y; Haber SN; Laruelle M
    Arch Gen Psychiatry; 2010 Mar; 67(3):231-9. PubMed ID: 20194823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.
    Kim CH; Koo MS; Cheon KA; Ryu YH; Lee JD; Lee HS
    Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1637-43. PubMed ID: 14513291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain.
    Borg J; Cervenka S; Kuja-Halkola R; Matheson GJ; Jönsson EG; Lichtenstein P; Henningsson S; Ichimiya T; Larsson H; Stenkrona P; Halldin C; Farde L
    Mol Psychiatry; 2016 Aug; 21(8):1077-84. PubMed ID: 26821979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.
    Brody AL; Mandelkern MA; Olmstead RE; Scheibal D; Hahn E; Shiraga S; Zamora-Paja E; Farahi J; Saxena S; London ED; McCracken JT
    Arch Gen Psychiatry; 2006 Jul; 63(7):808-16. PubMed ID: 16818870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PET imaging of neuroreceptors in schizophrenia.
    Sedvall G; Pauli S; Karlsson P; Farde L; Nordström AL; Nyberg S; Halldin C
    Eur Neuropsychopharmacol; 1995; 5 Suppl():25-30. PubMed ID: 8775755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Some aspects of the physiological role of dopamine as a synaptic transmitter in basal ganglia and caudate nucleus].
    Kostowski W
    Acta Physiol Pol; 1972; 23():97-114. PubMed ID: 4338739
    [No Abstract]   [Full Text] [Related]  

  • 59. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.
    Kasper S; Tauscher J; Küfferle B; Barnas C; Pezawas L; Quiner S
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():83-9. PubMed ID: 10654113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients.
    Buchsbaum MS; Wu JC; DeLisi LE; Holcomb HH; Hazlett E; Cooper-Langston K; Kessler R
    Biol Psychiatry; 1987 Apr; 22(4):479-94. PubMed ID: 2882788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.